AJANTA PHARMA LTD. - 532331 - Closure of Trading Window
Pursuance to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 (as amended from time to time) and the Company's Code of Conduct for Prevention of Insider Trading, the trading window for dealing in securities of the Company shall remain closed up to 48 hours after the conclusion of the Board Meeting scheduled to be held on Friday, 10th March 2023. AJANTA PHARMA LTD. - 532331 - Board Meeting Intimation for Buy Back Of Equity Shares
AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/03/2023 ,inter alia, to consider and approve the proposal for buyback of the equity shares of the Company and matters related / incidental thereto. AJANTA PHARMA LTD. - 532331 - Reply To Clarification Sought
Please find attached herewith reply to clarification sought. AJANTA PHARMA LTD. - 532331 - Clarification sought from Ajanta Pharma Ltd
The Exchange has sought clarification from Ajanta Pharma Ltd on March 3, 2023, with reference to Movement in Volume.The reply is awaited. AJANTA PHARMA LTD. - 532331 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI Listing Regulations, we would like to inform you that Registrar and Transfer Agent of Company, M/s. Link Intime India Private Limited has received intimation for loss of share certificate and request for issuance of duplicate share certificate from a shareholder AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Further to our communication dated 2nd February 2023 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 1st February 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link: https://ajantapharma.com//images/EarningsCallTranscriptQ3(Oct-Dec)2022-23.pdf AJANTA PHARMA LTD. - 532331 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Information on loss of share certificate AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose copies of Postal Ballot Notice of the company published in Economic Times (English) & Navshakti (Marathi), on Wednesday, 8th February 2023. AJANTA PHARMA LTD. - 532331 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Further to our letter dated 1st February 2023, please find enclosed herewith Postal Ballot Notice together with the Explanatory Statement seeking approval of members of the Company for reappointment and remuneration of Mr. Yogesh Agrawal as the Managing Director and Mr. Rajesh Agrawal as the Joint Managing Director. The Postal Ballot notice has been sent by e-mail on 7th February 2023 to the members who have registered their e-mail IDs with Depository Participant(s) or with the Company. E-voting period will commence from Wednesday, 8th February 2023, IST at 9.00 a.m. and will end on Thursday, 9th March 2023 IST at 5.00 p.m.
Buy Ajanta Pharma; target of Rs 1410: Motilal Oswal
Motilal Oswal is bullish on Ajanta Pharma recommended buy rating on the stock with a target price of Rs 1410 in its research report dated February 01, 2023.